nontubercul
mycobacteria
ntm
ubiquit
bacteria
environment
origin
includ
wide
divers
number
speci
caus
diseas
human
preval
ntm
lung
diseas
unexpectedli
increas
industri
countri
consist
uncov
recent
studi
key
issu
remain
determin
whether
ntm
true
singl
promot
evolv
lung
diseas
chronic
airway
colon
among
other
standard
diagnosi
ntm
lung
diseas
guidelin
ntm
diagnosi
american
thorac
societi
at
infecti
diseas
societi
america
idsa
british
thorac
societi
bt
requir
isol
growth
ntm
strain
least
two
separ
sampl
patient
human
host
pathogen
ntm
relationship
still
poorli
understood
ntm
virul
highli
variabl
one
speci
anoth
ntm
lung
diseas
strongli
associ
preexist
pulmonari
condit
chronic
obstruct
pulmonari
diseas
copd
cystic
fibrosi
idiopath
bronchiectasi
prior
activ
tuberculosi
pneumoconiosi
also
frequent
associ
genet
acquir
system
immun
defici
defect
pathway
inflammatori
cytokin
interleukin
il
tumor
necrosi
factor
tnf
interferon
ifn
immunosuppress
treatment
includ
therapi
corticosteroid
solidorgan
transplant
acquir
immun
defici
syndrom
aid
human
immunodefici
viru
hiv
infect
howev
may
also
occur
individu
without
recogn
sever
immun
local
system
defici
absenc
patent
predisposit
ntm
diseas
overrepres
among
specif
morphotyp
slender
women
low
bodi
fat
treatment
decis
ntm
lung
diseas
challeng
debat
patient
benefit
treatment
accord
medic
background
comorbid
clinic
statu
radiolog
featur
causal
ntm
strain
assess
clinic
microbiolog
radiolog
respons
treatment
standard
well
focus
ntm
lung
diseas
adult
without
system
immunodefici
met
at
criteria
guidelin
base
comparison
group
treat
untreat
patient
primari
object
identifi
factor
associ
physician
decis
initi
antintm
treatment
secondari
object
studi
outcom
upon
treatment
propos
standard
evalu
diagnosi
decis
make
treatment
ntm
lung
diseas
adult
without
system
immunodefici
conduct
retrospect
observ
singlecent
studi
januari
februari
month
among
adult
yearold
without
system
immunosuppress
present
ntm
lung
diseas
exclus
criteria
hiv
infect
cystic
fibrosi
primari
ciliari
dyskinesia
activ
malign
diseas
solidorgan
transplant
ongo
immunosuppress
treatment
tnf
inhibitor
highdos
corticosteroid
mgkg
day
case
identif
base
crossreferenc
databas
mycobacteria
laboratori
depart
infecti
pulmonari
diseas
patient
elig
inclus
ntm
lung
diseas
cohort
match
criteria
previous
defin
atsidsa
bt
guidelin
minimum
requir
clinic
microbiolog
follow
criteria
pulmonari
symptom
associ
multifoc
bronchiectasi
multipl
small
nodul
comput
tomographi
ct
scan
ii
proper
exclus
diagnos
iii
ntmposit
cultur
result
least
two
separ
expector
sputum
sampl
ntmposit
cultur
result
least
one
bronchial
wash
lavag
patient
characterist
diagnosi
collect
order
perform
analysi
select
variabl
demograph
histori
predispos
factor
underli
pulmonari
diseas
comorbid
pulmonari
function
test
respiratori
bacteri
mycolog
coinfect
definit
similar
ntm
criteria
name
posit
cultur
isol
speci
least
two
separ
expector
sputum
sampl
posit
cultur
result
least
one
bronchial
wash
lavag
immunolog
statu
nutrit
statu
clinic
featur
microbiolog
assess
identif
ntm
speci
posit
ntm
cultur
sampl
cultur
convers
radiolog
featur
highresolut
ctscan
fibrocavitari
diseas
nodularbronchiectasi
diseas
prior
treatment
ntm
lung
diseas
treatment
combin
durat
outcom
retrospect
observ
natur
studi
lack
modif
patient
manag
need
inform
consent
waiv
author
ethic
committe
lyon
univers
hospit
ethiqu
hospic
civil
de
lyon
approv
studi
number
independ
expert
chest
radiologist
blind
patient
inform
retrospect
review
ctscan
perform
without
inject
intraven
contrast
media
assign
random
order
diagnosi
six
month
treatment
follow
untreat
patient
number
size
caviti
i
wall
thick
evalu
lung
window
set
nodular
opac
i
mm
cluster
small
nodul
mm
treeinbud
pattern
presenc
bronchiectasi
lobe
multifoc
bronchiectasi
evalu
base
number
size
lesion
expert
classifi
lesion
improv
stabl
worsen
primari
endpoint
identifi
factor
significantli
involv
decis
initi
antintm
treatment
patient
refer
physician
secondari
endpoint
assess
clinic
radiolog
outcom
upon
antintm
treatment
comparison
treatment
base
find
standard
apprais
propos
assist
diagnosi
manag
treatment
decis
ntm
lung
diseas
adult
without
alter
system
immun
descript
data
use
estim
frequenc
studi
variabl
express
count
percentag
dichotom
variabl
median
interquartil
rang
iqr
continu
valu
number
miss
valu
exclud
denomin
nonparametr
statist
method
fisher
exact
test
test
mannwhitney
u
test
use
compar
group
appropri
probabl
treatment
initi
time
evalu
kaplanmei
surviv
curv
analysi
group
comparison
use
logrank
mantelcox
test
stepwis
binari
logist
regress
analysi
use
assess
determin
treatment
initi
express
odd
ratio
confid
interv
ci
check
variabl
interact
variabl
medic
mean
pvalu
obtain
univari
analysi
includ
final
multivari
model
valu
p
consid
signific
analys
perform
use
spss
softwar
version
spss
chicago
il
patient
elig
atsidsa
ntm
lung
diseas
criteria
patient
includ
studi
receiv
receiv
antintm
treatment
fig
median
age
interquartil
rang
iqr
yearold
malefemal
ratio
etiolog
ntm
agent
mycobacterium
avium
n
chimaera
n
xenopii
n
intracellular
n
simia
n
kansasii
n
abscessu
n
three
patient
concomit
ntm
lung
diseas
importantli
evid
ntm
lung
diseas
led
diagnos
six
underli
chronic
lung
diseas
genet
document
cystic
fibrosi
yearold
women
descript
analysi
patient
characterist
significantli
differ
except
lower
bmi
p
higher
number
previous
known
ntm
lung
diseas
p
treat
versu
untreat
patient
tabl
notabl
percentag
miss
data
diagnosi
acknowledg
activ
tobacco
smoke
n
respiratori
function
test
n
patient
walk
test
baselin
arteri
blood
oxygen
level
n
ctscan
follow
within
month
diagnosi
untreat
patient
n
factor
lead
patient
refer
physician
initi
antintm
treatment
assess
use
bivari
analysi
among
factor
significantli
associ
treatment
bmi
odd
ratio
confid
interv
ci
p
prior
antintm
treatment
ci
p
hemoptysi
ci
p
presenc
excav
lung
ctscan
ci
p
aspergillu
spp
coinfect
ci
p
tabl
multivari
analysi
aspergillu
spp
coinfect
singl
independ
factor
associ
antintm
treatment
ci
p
tabl
probabl
treatment
initi
time
accord
presenc
target
variabl
investig
probabl
significantli
higher
case
bmi
vs
p
hemoptysi
vs
hemoptysi
p
aspergillu
spp
coinfect
vs
coinfect
p
pulmonari
excav
vs
excav
p
fig
b
c
respect
treat
group
receiv
antintm
drug
among
receiv
macrolid
part
firstlin
regimen
median
antintm
treatment
durat
iqr
week
thirteen
treat
patient
develop
least
one
antimicrobialrel
advers
event
among
gastrointestin
disord
n
impair
blood
cell
count
n
cholestat
andor
cytolyt
hepat
n
accord
physician
judgment
clinic
stabil
improv
obtain
treat
patient
respect
patient
median
followup
diagnosi
assess
iqr
month
eightyf
ctscan
review
compar
assess
treatment
cours
followup
untreat
subset
median
interv
initi
ntm
treatment
date
assess
imag
iqr
week
although
n
n
experienc
regress
stabil
pulmonari
lesion
treat
patient
rate
differ
untreat
patient
n
n
regress
stabil
cours
followup
respect
tabl
final
allcaus
mortal
differ
treat
untreat
group
although
lost
followup
high
untreat
group
n
regard
four
patient
deceas
n
treat
group
n
untreat
group
caus
mortal
link
underli
diseas
rather
ntmrelat
mortal
present
studi
treat
patient
character
bmi
presenc
hemoptysi
excav
aspergillu
spp
coinfect
prior
antintm
treatment
aspergillu
spp
coinfect
independ
factor
associ
treatment
initi
singl
studi
five
english
center
recent
address
factor
influenc
antintm
treatment
initi
use
similar
retrospect
design
treat
untreat
cohort
comparison
except
differ
inclus
criteria
allow
nonaidshiv
immunosuppress
patient
treat
untreat
subset
respect
evalu
multivari
analysi
patient
increas
odd
antintm
treatment
case
cavit
ct
imag
night
sweat
weight
loss
three
four
criteria
part
guidelin
criteria
lead
decis
antintm
treatment
reflect
degre
sever
ntm
lung
diseas
link
progress
impair
respiratori
condit
current
problemat
ntm
lung
diseas
shift
distinguish
colon
infect
toward
differenti
stabl
poorli
activ
vs
progress
activ
ntm
diseas
latter
respons
structur
lung
damag
riskbenefit
analysi
includ
prescrib
recommend
longterm
multidrug
regimen
concern
suboptim
cure
rate
frequent
report
drugrel
side
effect
support
argument
other
alreadi
shown
physician
atsidsa
guidelin
adher
moder
confirm
trend
intuit
clinic
behavior
mostli
base
evid
sever
andor
patent
progress
diseas
multicent
studi
report
sampl
us
physician
treat
patient
avium
complex
mac
lung
diseas
overal
n
patient
mac
lung
diseas
receiv
type
antintm
treatment
physician
prescrib
antibiot
regimen
consist
atsidsa
guidelin
anoth
studi
conduct
franc
shown
among
cohort
ntm
lung
diseas
receiv
appropri
treatment
match
atsidsa
guidelin
inappropri
prescript
mostli
relat
shorter
treatment
durat
month
less
andor
offrecommend
regimen
particularli
exclud
macrolid
combin
use
singledrug
macrolid
regimen
acknowledg
guidelin
specifi
treatment
macassoci
lung
diseas
hivneg
individu
threetimesweekli
drug
regimen
upon
cultur
convers
therapi
year
may
favor
treatment
complianc
patient
bronchiectasi
ntm
lung
diseas
higher
preval
sensit
aspergillu
patient
ntmfree
bronchiectasi
allerg
airway
manifest
respons
aspergillu
term
aspergillusrel
lung
diseas
spectrum
go
aspergillusinduc
hypersensit
sever
allerg
bronchopulmonari
aspergillosi
abpa
coexist
ntm
aspergillu
lung
airway
justifi
need
test
aspergillu
serolog
total
serum
immunoglobulin
ig
e
aspergillusspecif
ige
level
well
mycolog
direct
examin
cultur
sputum
bronchial
aspir
presenc
filament
fungi
diagnosi
algorithm
patient
ntm
lung
diseas
activ
coinfect
ntm
aspergillu
spp
also
describ
patient
ntm
lung
diseas
develop
chronic
form
pulmonari
aspergillosi
definit
manag
revisit
recent
updat
guidelin
radiograph
improv
may
hamper
concomit
lung
diseas
limit
potenti
resolut
consolid
radiolog
abnorm
previou
studi
investig
radiolog
respons
treatment
show
consist
result
found
present
studi
although
antintm
treatment
led
improv
stabil
lesion
major
patient
modif
significantli
differ
untreat
group
went
ctscan
follow
indic
antintm
treatment
lead
radiolog
abnorm
revers
present
studi
strength
limit
strength
studi
largest
cohort
far
ntm
lung
diseas
patient
without
system
immunodefici
exhaust
data
collect
blind
radiolog
assess
acknowledg
bias
contribut
mitig
conclus
studi
conduct
singl
center
import
differ
physician
manag
result
lack
consist
treatment
decis
make
number
miss
data
addit
ctscan
perform
fix
interv
particularli
untreat
subset
patient
final
treatment
durat
outcom
criteria
standard
prevent
properli
assess
treatment
efficaci
use
consensu
definit
key
outcom
paramet
use
treatment
ntm
lung
diseas
releas
recent
harmon
data
collect
regard
ntm
treatment
futur
research
necessari
better
defin
criteria
associ
progress
activ
ntm
diseas
immunocompet
set
concret
preliminari
studi
led
implement
institut
standard
apprais
diagnosi
ntm
lung
diseas
particular
set
tabl
aim
provid
futur
basi
develop
diagnosi
score
system
support
antintm
treatment
decis
futur
studi
focu
well
relev
ct
imag
variabl
associ
respons
treatment
time
may
appli
futur
clinic
trial
assess
treatment
outcom
summari
main
factor
support
antintm
treatment
decis
immunocompet
low
bmi
hemoptysi
lung
excav
prior
antintm
treatment
aspergillu
pp
coinfect
latter
independ
factor
antintm
treatment
achiev
radiolog
abnorm
revers
pulmonari
lesion
assess
show
differ
treat
untreat
patient
diagnosi
ntm
lung
diseas
immunocompet
patient
requir
investig
presenc
chronic
pulmonari
underli
diseas
